ASCO GU Symposium 2024
ASCO GU Symposium 2024
Advertisement
Jérémie Calais, MD, PhDAdvanced Imaging | February 15, 2024
Dr. Calais explains the utility of PSMA PET prior to RT for unfavorable intermediate-risk or high-risk prostate cancer.
View More
Saby George, MD, FACPAdvanced Renal Cell Carcinoma | February 15, 2024
Dr. Saby George continues with the survival implications and ramifications from the CheckMate 214 long-term data.
Saby George, MD, FACPAdvanced Renal Cell Carcinoma | February 15, 2024
Dr. Saby George provides details on CheckMate 67T for the utility of subcutaneous nivolumab for advanced or metastatic ccRCC.
Thomas Powles, MBBS, MRCP, MDAdvanced Urothelial Carcinoma | February 13, 2024
Dr. Powles offers his thoughts on the latest OS data from EV-302 for patient subgroups and immune-related toxicity.
Thomas Powles, MBBS, MRCP, MDAdvanced Renal Cell Carcinoma | February 13, 2024
Dr. Powles gives his unique feedback on what to make of KEYNOTE-564 and how aRCC frontline options should be compared.
Vadim Koshkin, MDUrothelial Carcinoma | February 12, 2024
The outcomes related to sacituzumab govitecan for patients with variant histologies are highlighted.
Vadim Koshkin, MDAdvanced Urothelial Carcinoma | February 12, 2024
The potential for sequencing erdafitinib and EV for patients with FGFR2/3-altered disease is considered.
Vadim Koshkin, MDAdvanced Urothelial Carcinoma | February 12, 2024
The impact of squamous and other histologies on outcomes with EV are dissected.
Vadim Koshkin, MDAdvanced Urothelial Carcinoma | February 12, 2024
The design of UNITE, patients sampled, and outcomes with EV after switch maintenance avelumab are explored.
Karine Tawagi, MDUrothelial Carcinoma | February 8, 2024
Dr. Tawagi provides her thoughts on treatment selection and sequencing for mUC, especially after progression on EV/pembro.
Monty Pal, MDASCO GU Symposium 2024 | February 6, 2024
CheckMate 9ER, 67T and KEYNOTE-564 are discussed.
Sia Daneshmand, MDASCO GU Symposium 2024 | February 6, 2024
Drs. Daneshmand and Wallis highlight two trials in progress in NMIBC: ABLE-41 and PIVOT-006.
Regina Barragan-Carrillo, MDASCO GU Symposium 2024 | January 30, 2024
Dr. Barragán-Carrillo explains the potential benefits of camu camu in reducing tumor size.
Daniel M. Geynisman, MDASCO GU Symposium 2024 | January 30, 2024
Dr. Geynisman highlights the CheckMate 274 study into long-term survival following treatment with adjuvant nivolumab.
Petros Grivas, MD, PhDASCO GU Symposium 2024 | February 5, 2024
Dr. Grivas describes the advancements in the discussion around avelumab maintenance at this year's meeting.
Brian Rini, MD, FASCOASCO GU Symposium 2024 | January 30, 2024
Dr. Brian Rini discusses KEYNOTE-564 long-term survival data and LITESPARK-005 PROs.
Elizabeth Plimack, MD, MS, FASCOASCO GU Symposium 2024 | January 30, 2024
Dr. Plimack comments on long-term survival data from nivolumab/ipilimumab in the CheckMate 214 study as well as other data.
Tanya JindalASCO GU Symposium 2024 | February 1, 2024
Tanya Jindal discusses the safety and efficacy of neoadjuvant atezolizumab prior to radical cystectomy for MIBC.
Guru P. Sonpavde, MDASCO GU Symposium 2024 | February 4, 2024
Dr. Sonpavde provides a detailed overview of 2 of the bladder cancer trials of note: AMBASSADOR and PemCab.
Emily MenendezASCO GU Symposium 2024 | January 30, 2024
While IV nivolumab has improved patient outcomes, there is a need for different administration options to improve efficiency.
Advertisement
Advertisement
Advertisement